Clinical Trial Update: Efficacy and Safety of Turoctocog Alfa Pegol (N8-GP) for Prophylaxis and Treatment of Bleeding Episodes in Previously Treated Chinese Patients With Haemophilia A (pathfinder10) [Phase 3]

View source ↗

Summary

Phase 3 study evaluating the efficacy and safety of N8-GP (turoctocog alfa pegol) for prophylaxis and treatment of bleeding episodes in previously treated Chine…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Haemophilia

Drugs mentioned

• N8-GP (Turoctocog alfa pegol) (turoctocog alfa pegol)

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Haemophilia A | Phase 3 | Status: COMPLETED | Results posted: 2024-01-18